Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

BACKGROUND: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. METHODS: An...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sweiss, Nadera J., Noth, Imre, Mirsaeidi, Mehdi, Zhang, Wei, Naureckas, Edward T., Hogarth, D. Kyle, Strek, Mary, Caligiuri, Philip, Machado, Roberto F, Niewold, Timothy B, Garcia, Joe G.N., Pangan, Aileen L., Baughman, Robert P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134103/
https://ncbi.nlm.nih.gov/pubmed/24751453
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados